Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel

Ruo-Xi Gu; Xiao-Zeng Wang; Jing Li; Jie Deng; Xing-Xing Li; Jiao Wang

Your Location：

Home >

Browse articles >

Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel

RESEARCH | Updated：2022-12-27

- Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel
- Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel
- MMR 2017年4卷第2期页码：70-79
- Affiliations：
  
  Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China
- Author bio：
  
  *: wxiaozeng@163.com
- Funds：
  
  National Key Technology R&D Program in the "Twelfth Five-Year" Plan of China(2011BAI11B07)
- DOI：
  中图分类号：
- 纸质出版：2017-06
- Accepted：
Scan QR Code
Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel[J]. MMR, 2017,4(2):70-79.

Ruo-Xi Gu, Xiao-Zeng Wang, Jing Li, et al. Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel[J]. Military Medical Research, 2017, 4(2): 70-79.
Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel[J]. MMR, 2017,4(2):70-79. DOI：

Ruo-Xi Gu, Xiao-Zeng Wang, Jing Li, et al. Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel[J]. Military Medical Research, 2017, 4(2): 70-79. DOI：

摘要

Abstract

Background:

This study evaluated the effect of omeprazole or pantoprazole on platelet reactivity in non-STsegment elevation acute coronary syndrome (NSTE-ACS) patients receiving clopidogrel.

Methods:

Consecutive patients with NSTE-ACS (

=620) from general hospital of Shenyang Military Command were randomized to the omeprazole or pantoprazole (20mg/d) group (1:1)

and received routine dual antiplatelet treatment. Patients’ reversion rate of adenosine diphosphate-induced platelet aggregation (ADP-PA) was assessed at baseline

12 to 24h after administration of medication

and after 72h of percutaneous coronary intervention (PCI). The primary endpoint of the study was platelet reactivity assessed with ADP-PA at 30 days after PCI. Adverse events (AEs) were recorded for 30-day and 180-day follow-up periods.

Results:

There were no significant differences between both the groups in platelet response to clopidogrel at 12–24h after drug administration (54.09%±18.90%

. 51.62%±19.85%

=0.12)

72h after PCI (52.15%±19.45%

. 49.66%±20.05%

=0.18)

and 30 days after PCI (50.44%±14.54%

. 48.52%±15.08%

=0.17). The rate of AEs did not differ significantly between groups during the 30-day (15.2%

. 14.8%

=0.91) and 180-day (16.5%

. 14.5%

=0.50) follow-up periods after PCI.

Conclusion:

The addition of omeprazole or pantoprazole to clopidogrel did not restrict the effect of platelet aggregation by reducing the conversion of clopidogrel. Compared with clopidogrel alone

pantoprazole-clopidogrel and omeprazole-clopidogrel combinations did not increase the incidence of adverse clinical events during 30-day and 180-day follow-up periods after PCI.

关键词

Keywords

references

Bhatt DL , Scheiman J , Abraham NS , Antman EM , Chan FK , Furberg CD , et al . ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents . J Am Coll Cardiol . 2008 ; 52 : 1502 - 17 .

Tsukahara K , Kimura K , Morita S , Ebina T , Kosuge M , Hibi K , et al . Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effect . J Cardiol . 2011 ; 57 : 275 - 82 .

Bhatt DL , Cryer BL , Contant CF , Cohen M , Lanas A , Schnitzer TJ , et al . Clopidogrel with or without omeprazole in coronary artery disease . N Engl J Med . 2010 ; 363 : 1909 - 17 .

Simon T , Steg PG , Gilard M , Blanchard D , Bonello L , Hanssen M , et al . Clinical events as a function of proton pump inhibitor use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry . Circulation . 2011 ; 123 : 474 - 82 .

Abraham NS , Hlatky MA , Antman EM , Bhatt DL , Bjorkman DJ , Clark CB , et al . ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use . Am J Gastroenterol . 2010 ; 105 ( 12 ): 2533 - 49 .

Ho PM , Maddox TM , Wang L , Fihn SD , Jesse RL , Peterson ED , et al . Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome . JAMA . 2009 ; 301 : 937 - 44 .

Juurlink DN , Gomes T , Ko DT , Szmitko PE , Austin PC , Tu JV , et al . A population-based study of the drug interaction between proton pump inhibitors and clopidogrel . CMAJ . 2009 ; 180 : 713 - 8 .

Huang CC , Chen YC , Leu HB , Chen TJ , Lin SJ , Chan WL , et al . Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention . Am J Cardiol . 2010 ; 105 : 1705 - 9 .

Stockl KM , Le L , Zakharyan A , Harada AS , Solow BK , Addiego JE , et al . Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor . Arch Intern Med . 2010 ; 170 : 704 - 10 .

Ray WA , Murray KT , Griffin MR , Chung CP , Smalley WE , Hall K , et al . Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study . Ann Intern Med . 2010 ; 152 : 337 - 45 .

Dunn SP , Steinhubl SR , Bauer D , Charnigo RJ , Berger PB , Topol EJ , et al . Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials . J Am Heart Assoc . 2013 ; 2 ( 1 ): e004564 .

Siller-Matula JM , Spiel AO , Lang IM , Kreiner G , Christ G , Jilma B , et al . Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel . Am Heart J . 2009 ; 157 ( 1 ): 148.e1–5 .

Savi P , Pereillo JM , Uzabiaga MF , Combalbert J , Picard C , Maffrand JP , et al . Identification and biological activity of the active metabolite of clopidogrel . Thromb Haemost . 2000 ; 84 : 891 - 6 .

Li XQ , Andersson TB , Ahlström M , Weidolf L . Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities . Drug Metab Dispos . 2004 ; 32 : 821 - 7 .

Chen CH , Yang JC , Uang YS , Lin CJ . Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel . Biopharm Drug Dispos . 2012 ; 33 : 278 - 83 .

Bovill EG , Terrin ML , Stump DC , Berke AD , Frederick M , Collen D , et al . Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial . Ann Intern Med . 1991 ; 115 : 256 - 65 .

Lai KC , Lam SK , Chu KM , Wong BC , Hui WM , Hu WH , et al . Lansoprazole for the prevention of recurrences of ulcer complications from long-term lowdose aspirin use . N Engl J Med . 2002 ; 346 ( 26 ): 2033 - 8 .

Hollopeter G , Jantzen HM , Vincent D , Li G , England L , Ramakrishnan V , et al . Identification of the platelet ADP receptor targeted by antithrombotic drugs . Nature . 2001 ; 409 ( 6817 ): 202 - 7 .

Brandt JT , Close SL , Iturria SJ , Payne CD , Farid NA , Ernest 2nd CS , et al . Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel . J Thromb Haemost . 2007 ; 5 ( 12 ): 2429 - 36 .

Sibbing D , Morath T , Stegherr J , Braun S , Vogt W , Hadamitzky M , et al . Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel . Thromb Haemost . 2009 ; 101 ( 4 ): 714 - 9 .

Kazui M , Nishiya Y , Ishizuka T , Hagihara K , Farid NA , Okazaki O , et al . Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite . Drug Metab Dispos . 2010 ; 38 ( 1 ): 92 - 9 .

Sangkuhl K , Klein TE , Altman RB . Clopidogrel pathway . Pharmacogenet Genomics . 2010 ; 20 ( 7 ): 463 - 5 .

Furuta T , Shirai N , Sugimoto M , Nakamura A , Hishida A , Ishizaki T , et al . Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies . Drug Metab Pharmacokinet . 2005 ; 20 : 153 - 67 .

Kwok CS , Loke YK . Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel . Aliment Pharmacol Ther . 2010 ; 31 : 810 - 23 .

Kenngott S , Olze R , Kollmer M , Bottheim H , Laner A , Holinski-Feder E , et al . Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur J Med Res . 2010 ; 15 ( 5 ): 220 - 4 .

Breet NJ , van Werkum JW , Bouman HJ , Kelder JC , Ruven HJ , Bal ET , et al . Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation . JAMA . 2010 ; 303 ( 8 ): 754 - 62 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据